AIxCrypto Secures Web3 License in UAE, Enhancing Global Expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Source: Newsfilter
- Regulatory Legitimacy Boost: AIxCrypto's acquisition of a Web3 license in Ras Al Khaimah Innovation City positions the company strategically within a global blockchain hub, enhancing regulatory certainty and capital access.
- Business Expansion Opportunities: The license provides a clear framework for developing DeFi protocols and broader Web3 commercial activities, supporting AIxCrypto's long-term growth in the rapidly evolving digital asset economy.
- Banking Partnerships and Compliance Advantages: The licensing in RAK enables AIxCrypto to establish partnerships with local banks, access fiat on-ramps, and enhance credibility with payment processors and OTC desks, thereby improving fundraising capabilities.
- Attracting Institutional Capital: AIxCrypto's licensed presence in RAK signals commitment to the Middle East, appealing to sovereign wealth funds and investment institutions, which is crucial for accessing additional investment opportunities.
Analyst Views on AIXC
About AIXC
AIxCrypto Holdings, Inc., formerly Qualigen Therapeutics, Inc., is focused on building an ecosystem that integrates Artificial Intelligence (AI) and blockchain, bridging Web2 and Web3. This ecosystem unites a decentralized protocol, distributed network, AI DePIN and EAI RWA value regeneration, and a DeAI Agent product and technology platform designed to achieve optimal trading performance. Its core products include the BesTrade DeAI Agent and the AIxC ecosystem products. Its crypto business, CXC10, is centered on three growth engines which include six key products: C - Crypto 10 (C10) as Value Anchor, X - DeAI Agent, and C - RWA & Ecosystem Tokens. C - Crypto 10 (C10) as Value Anchor - through the C10 Digital Asset Treasury, C10 Index, and a potential C10 ETF. C - RWA & Ecosystem Tokens - including the C10 Stablecoin and the EAI + Crypto Dual-Bridge Real World Asset product, bridging traditional assets with Web3. It also develops and commercializes oncology and immunology therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
